![]() liver or neurological damage as reported after CAR or TCR gene therapy or graft-versus-host disease (GvHD) after alloSCT, due to on-target recognition of healthy organs by the adoptively transferred T cells. In addition to strong anti-tumor immunity, immunotherapy can cause life-threatening toxicity, i.e. CAR T-cell therapy specific for CD19 has successfully been used to treat patients with B-cell malignancies. Another effective approach is targeted therapy by chimeric antigen receptor (CAR) or T-cell receptor (TCR) gene transfer. After allogeneic hematopoietic stem cell transplantation (alloSCT), anti-tumor immunity is mediated by donor T cells recognizing the malignant cells of the patient. In conclusion, our microarray database provides a relevant platform to analyze and select candidate antigens with hematopoietic (lineage)-restricted expression as potential targets for immunotherapy of hematological cancers.Ĭellular immunotherapy of hematological cancers has proven very effective. Detailed gene expression profiles were generated for various minor histocompatibility antigens and B-cell surface antigens to illustrate the value of the microarray dataset to estimate efficacy and toxicity of candidate targets for immunotherapy. Microarray data were validated by quantitative RT-PCR showing strong correlations between both platforms. Gene expression was investigated by Illumina HT12.0 microarrays and quality control analysis was performed to confirm the cell-type origin and exclude contamination of non-hematopoietic cell samples with peripheral blood cells. Non-hematopoietic cells were also cultured in the presence of IFN-γ to analyze gene expression under inflammatory circumstances. We performed microarray gene expression analysis of hematological malignancies of different origins, healthy hematopoietic cells and various non-hematopoietic cell types from organs that are often targeted in detrimental immune responses after allogeneic stem cell transplantation leading to graft-versus-host disease. Therefore, detailed tissue distribution analysis is essential to estimate potential efficacy and toxicity of candidate targets for immunotherapy of hematological malignancies. However, dependent on the tissue distribution of the antigens that are targeted, anti-tumor responses can be accompanied by undesired side effects. Cellular immunotherapy has proven to be effective in the treatment of hematological cancers by donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation and more recently by targeted therapy with chimeric antigen or T-cell receptor-engineered T cells. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |